13C-lactose blood test for lactose intolerance


Indications for the Lactoin Test

10 to 15 percent of the population in Germany, up to 60 percent of the southern European population, and about half of all people worldwide suffer from chronic lactose intolerance. This is attributed to the insufficient production of the enzyme lactase. Since an undiscovered lactose intolerance can lead to gastric colic and diarrhoea, this test is also useful for small children. While the primary congenital form of lactase deficiency occurs comparatively rarely, most cases are secondary lactose deficiency, often associated with other diseases such as celiac disease or Crohn's disease. The acquired variant, for example after viral infections, is also becoming increasingly important.

Lactoin Test principle

The test is evaluated by elemental analysis or gas chromatography, followed by mass spectroscopy. Unmetabolised lactose with a reduced 13C-lactose content is measured in the blood, and possibly in the stool. This product is patented in the USA and the EU, and approval is in preparation.

Lactoin Patent

  • EP1320757, Method for diagnosing lactose intolerance and diagnostic kit for carrying out the method, European patent, 30.11.2005
  • US7037487, Method for diagnosing lactose intolerance and diagnostic kit for performing the method, US Patent, 02.05.2006
  • WO2002027325, Method for Diagnosing Lactose Intolerance and Diagnosis Kit For Carrying Out The Method, International Patent, 04.04.2002